My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 330

    1.

    Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

    Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ.

    Diabetes. 2004 Jul;53(7):1813-23. Erratum in: Diabetes. 2006 Mar;55(3):862. Thorpe, Susan M [corrected to Thorpe, Susan R]. PMID: 15220206 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.

    Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB.

    Circulation. 2007 Apr 24;115(16):2178-87. Epub 2007 Apr 9.PMID: 17420349 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

    Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA.

    J Am Soc Nephrol. 2004 Aug;15(8):2125-38.PMID: 15284298 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

    Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME.

    FASEB J. 2003 Sep;17(12):1762-4. Epub 2003 Jul 18.PMID: 12958202 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.

    Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ.

    Circulation. 2002 Jul 9;106(2):246-53.PMID: 12105166 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.

    Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM.

    Circ Res. 2003 Apr 18;92(7):785-92. Epub 2003 Mar 6.PMID: 12623881 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.

    Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM.

    Diabetes. 2004 Nov;53(11):2921-30.PMID: 15504973 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.

    Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA.

    Diabetes. 2008 Sep;57(9):2461-9. Epub 2008 May 28.PMID: 18511846 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice.

    Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, Vlassara H.

    Atherosclerosis. 2003 Jun;168(2):213-20.PMID: 12801603 [PubMed - indexed for MEDLINE]Related articles

    10.

    The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment.

    Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, Hellstrom WJ.

    J Sex Med. 2006 Mar;3(2):242-50; discussion 250-2.PMID: 16490017 [PubMed - indexed for MEDLINE]Related articles

    11.

    Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.

    Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm KA.

    Circulation. 2004 Mar 30;109(12):1536-42. Epub 2004 Mar 15.PMID: 15023892 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis.

    Cantero AV, Portero-Otín M, Ayala V, Auge N, Sanson M, Elbaz M, Thiers JC, Pamplona R, Salvayre R, Nègre-Salvayre A.

    FASEB J. 2007 Oct;21(12):3096-106. Epub 2007 May 15.PMID: 17504976 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.

    Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM.

    Nat Med. 1998 Sep;4(9):1025-31.PMID: 9734395 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats.

    Oturai PS, Christensen M, Rolin B, Pedersen KE, Mortensen SB, Boel E.

    Metabolism. 2000 Aug;49(8):996-1000.PMID: 10954016 [PubMed - indexed for MEDLINE]Related articles

    15.

    Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats.

    Cheng G, Wang LL, Long L, Liu HY, Cui H, Qu WS, Li S.

    Br J Pharmacol. 2007 Dec;152(8):1196-206. Epub 2007 Oct 29.PMID: 17965740 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.

    Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE.

    J Clin Invest. 1997 Mar 1;99(5):1016-27.PMID: 9062360 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

    Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, Cooper ME, Jandeleit-Dahm KA.

    Diabetologia. 2008 Sep;51(9):1731-40. Epub 2008 Jul 2.PMID: 18594792 [PubMed - indexed for MEDLINE]Related articles

    18.

    Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy.

    Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME.

    J Am Soc Nephrol. 2001 Oct;12(10):2098-107.PMID: 11562408 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.

    Jeyabal PV, Kumar R, Gangula PR, Micci MA, Pasricha PJ.

    Neurogastroenterol Motil. 2008 Mar;20(3):253-61. Epub 2007 Oct 17.PMID: 17971026 [PubMed - indexed for MEDLINE]Related articles

    20.

    Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage.

    Meng J, Sakata N, Takebayashi S, Asano T, Futata T, Nagai R, Ikeda K, Horiuchi S, Myint T, Taniguchi N.

    Atherosclerosis. 1998 Feb;136(2):355-65.PMID: 9543107 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity